HEPATOTOXICITY
See full prescribing information for complete boxed warning.
- TRADE NAME: Stivarga (Bayer)
- INDICATIONS: Metastatic colorectal cancer, gastrointestinal stomal tumors
- CLASS: Angiogenesis inhibitor / antiangiogenic agent, Tyrosine kinase inhibitor, Vascular endothelial growth factor (VEGF) inhibitor / antagonist
- HALF-LIFE: 28 hours
- FDA APPROVAL DATE: 09/27/2012
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Carbamazepine, Clarithromycin, CYP3A4 inducers and inhibitors, Grapefruit Juice, Itraconazole, Ketoconazole, Phenobarbital, Phenytoin, Posaconazole, Rifampin, St John's Wort, Telithromycin, Voriconazole
- See adverse reactions attributed to class:
Angiogenesis inhibitor / antiangiogenic agent
Vascular endothelial growth factor (VEGF) inhibitor / antagonist
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
